ReviewIntractable & rare diseases research2019
Incidence and prevalence of 121 rare diseases in China: Current status and challenges.
Review in Intractable & rare diseases research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Reconceiving orphan drug market exclusivity as a conditional public-law entitlement: a sustainable regulatory governance model with comparative lessons for China.Frontiers in medicine · 2026Article
- Epidemiology and distribution of 207 rare diseases in China: A systematic literature review.Intractable & rare diseases research · 2024Review
- Knowledge and Attitudes of Clinical Trials among Patients with Rare Diseases and the Guardians in China.Therapeutic innovation & regulatory science · 2024Article
- Diagnosis, treatment, and research status of rare diseases related to birth defects.Intractable & rare diseases research · 2023Review
- Incidence and prevalence of 121 rare diseases in China: Current status and challenges: 2022 revision.Intractable & rare diseases research · 2022Review
- Current status and trend of clinical development of orphan drugs in China.Orphanet journal of rare diseases · 2022Article
- Poor education and urgent information need for emergency physicians about rare diseases in China.Orphanet journal of rare diseases · 2022Article
- Real-World Prescription Patterns For Patients With Young-Onset Parkinson's Disease in China: A Trend Analysis From 2014 to 2019.Frontiers in pharmacology · 2022Article
- The global carrier frequency and genetic prevalence of Upshaw-Schulman syndrome.BMC genomic data · 2021Article
- Economic burden and health related quality of life of ultra-rare Gaucher disease in China.Orphanet journal of rare diseases · 2021Article
- A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China.Orphanet journal of rare diseases · 2021Article
- Innovation in Informatics to Improve Clinical Care and Drug Accessibility for Rare Diseases in China.Frontiers in pharmacology · 2021Article
- The urgent need to empower rare disease organizations in China: an interview-based study.Orphanet journal of rare diseases · 2020Article
- Determining the Topic Evolution and Sentiment Polarity for Albinism in a Chinese Online Health Community: Machine Learning and Social Network Analysis.JMIR medical informatics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to ascertain the current status of and challenges posed by the incidence and prevalence of rare diseases in China, this study teases out data on the incidence and prevalence of 121 rare diseases listed in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.